{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:06:46Z","timestamp":1791446806037,"version":"4.3.3"},"reference-count":104,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Heart Research Institute New Zealand Pathways Program","award":["1188218"],"award-info":[{"award-number":["1188218"]}]},{"name":"Australian Government Research Program","award":["1188218"],"award-info":[{"award-number":["1188218"]}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1188218"],"award-info":[{"award-number":["1188218"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Heart Research Institute","award":["1188218"],"award-info":[{"award-number":["1188218"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>TNF-related apoptosis-inducing ligand (TRAIL) was originally discovered, almost 20 years ago, for its ability to kill cancer cells. More recent evidence has described pleiotropic functions, particularly in the cardiovascular system. There is potential for TRAIL concentrations in the circulation to act as prognostic and\/or diagnostic factors for cardiovascular diseases (CVD). Pre-clinical studies also describe the therapeutic capacity for TRAIL signals, particularly in the context of atherosclerotic disease and diseases of the myocardium. Because diabetes mellitus significantly contributes to the progression and pathogenesis of CVDs, in this review we highlight recent evidence for the prognostic, diagnostic, and therapeutic potential of TRAIL signals in CVDs, and where relevant, the impact of diabetes mellitus. A greater understanding of how TRAIL signals regulate cardiovascular protection and pathology may offer new diagnostic and therapeutic avenues for patients suffering from CVDs.<\/jats:p>","DOI":"10.3390\/ijms24076725","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T04:52:14Z","timestamp":1680583934000},"page":"6725","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Prognostic, Diagnostic, and Therapeutic Potential of TRAIL Signalling in Cardiovascular Diseases"],"prefix":"10.3390","volume":"24","author":[{"given":"Elaina","family":"Kelland","sequence":"first","affiliation":[{"name":"Heart Research Institute, The University of Sydney, Sydney 2042, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha S.","family":"Patil","sequence":"additional","affiliation":[{"name":"Heart Research Institute, The University of Sydney, Sydney 2042, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Patel","sequence":"additional","affiliation":[{"name":"Heart Research Institute, The University of Sydney, Sydney 2042, Australia"},{"name":"Royal Prince Alfred Hospital, Sydney 2006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1723-2679","authenticated-orcid":false,"given":"Si\u00e2n P.","family":"Cartland","sequence":"additional","affiliation":[{"name":"Heart Research Institute, The University of Sydney, Sydney 2042, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Kavurma","sequence":"additional","affiliation":[{"name":"Heart Research Institute, The University of Sydney, Sydney 2042, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global Burden of Cardiovascular Diseases and Risk Factors, 1990\u20132019: Update From the GBD 2019 Study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007\u20132017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_3","first-page":"e984","article-title":"Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association","volume":"143","author":"Poirier","year":"2021","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","article-title":"Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family","volume":"271","author":"Pitti","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","article-title":"Identification and characterization of a new member of the TNF family that induces apoptosis","volume":"3","author":"Wiley","year":"1995","journal-title":"Immunity"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.1158\/0008-5472.CAN-08-0078","article-title":"Metastasis suppressor function of tumor necrosis factor-related apoptosis-inducing ligand-R in mice: Implications for TRAIL-based therapy in humans?","volume":"68","author":"Kemp","year":"2008","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"628332","DOI":"10.3389\/fmolb.2021.628332","article-title":"The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials","volume":"8","author":"Snajdauf","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/cdd.2012.90","article-title":"TRAIL induces necroptosis involving RIPK1\/RIPK3-dependent PARP-1 activation","volume":"19","author":"Arshad","year":"2012","journal-title":"Cell Death Differ."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12079-016-0364-4","article-title":"Autophagy is a regulator of TRAIL-induced apoptosis in NSCLC A549 cells","volume":"11","author":"Chen","year":"2017","journal-title":"J. Cell Commun. Signal."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1161\/CIRCRESAHA.109.206029","article-title":"TRAIL Promotes VSMC Proliferation and Neointima Formation in a FGF-2\u2013, Sp1 Phosphorylation\u2013, and NF\u03baB-Dependent Manner","volume":"106","author":"Chan","year":"2010","journal-title":"Circ. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/01.CIR.0000062702.60708.C4","article-title":"TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK Pathways","volume":"107","author":"Secchiero","year":"2003","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/JME-20-0037","article-title":"TRAIL induces proliferation in rodent pancreatic beta cells via AKT activation","volume":"66","author":"Kahraman","year":"2021","journal-title":"J. Mol. Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cartland, S.P., Genner, S.W., Zahoor, A., and Kavurma, M.M. (2016). Comparative Evaluation of TRAIL, FGF-2 and VEGF-A-Induced Angiogenesis In Vitro and In Vivo. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17122025"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7754","DOI":"10.1074\/jbc.M706927200","article-title":"TRAIL Stimulates Proliferation of Vascular Smooth Muscle Cells via Activation of NF-\u03baB and Induction of Insulin-like Growth Factor-1 Receptor","volume":"283","author":"Kavurma","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.277.5327.815","article-title":"An antagonist decoy receptor and a death domain-containing receptor for TRAIL","volume":"277","author":"Pan","year":"1997","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.atherosclerosis.2010.11.004","article-title":"Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults","volume":"215","author":"Volpato","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Osmancik, P., Teringova, E., Tousek, P., Paulu, P., and Widimsky, P. (2013). Prognostic value of TNF-related apoptosis inducing ligand (TRAIL) in acute coronary syndrome patients. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0053860"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kakareko, K., Rydzewska-Roso\u0142owska, A., Zbroch, E., and Hryszko, T. (2021). TRAIL and Cardiovascular Disease\u2014A Risk Factor or Risk Marker: A Systematic Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10061252"},{"key":"ref_19","first-page":"853","article-title":"Endothelial dysfunction in diabetes mellitus","volume":"3","author":"Hadi","year":"2007","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.thromres.2009.11.024","article-title":"Association of serum TRAIL level with coronary artery disease","volume":"125","author":"Mori","year":"2009","journal-title":"Thromb. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1177\/0003319710370961","article-title":"Possible Role of Osteoprotegerin and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand as Markers of Plaque Instability in Coronary Artery Disease","volume":"61","author":"Shaker","year":"2010","journal-title":"Angiology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.rmed.2018.10.018","article-title":"Decreased serum TRAIL is associated with increased mortality in smokers with comorbid emphysema and coronary artery disease","volume":"145","author":"Ajala","year":"2018","journal-title":"Respir. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.isci.2018.12.037","article-title":"TRAIL-Expressing Monocyte\/Macrophages Are Critical for Reducing Inflammation and Atherosclerosis","volume":"12","author":"Cartland","year":"2019","journal-title":"iScience"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wallentin, L., Eriksson, N., Olszowka, M., Grammer, T.B., Hagstr\u00f6m, E., Held, C., Kleber, M.E., Koenig, W., M\u00e4rz, W., and Stewart, R.A.H. (2021). Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. PLoS Med., 18.","DOI":"10.1371\/journal.pmed.1003513"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1177\/2047487317725017","article-title":"GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction","volume":"24","author":"Skau","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40620-018-0556-5","article-title":"Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease","volume":"32","author":"Feldreich","year":"2019","journal-title":"J. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/joim.13116","article-title":"Use of proteomics to identify biomarkers associated with chronic kidney disease and long-term outcomes in patients with myocardial infarction","volume":"288","author":"Edfors","year":"2020","journal-title":"J. Intern. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1007\/s00392-020-01729-3","article-title":"Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: Findings from the EXAMINE trial","volume":"110","author":"Ferreira","year":"2021","journal-title":"Clin. Res. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1538-7836.2011.04222.x","article-title":"Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: The Tromso Study","volume":"9","author":"Vik","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2020.03.030","article-title":"Serum osteoprotegerin as a long-term predictor for patients with stable coronary artery disease and its association with diabetes and statin treatment: A CLARICOR trial 10-year follow-up substudy","volume":"301","author":"Bjerre","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.amjcard.2011.09.043","article-title":"Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis","volume":"109","author":"Mogelvang","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.advms.2016.03.003","article-title":"Osteoprotegerin and osteoprotegerin\/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure","volume":"61","author":"Kuzniewski","year":"2016","journal-title":"Adv. Med. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.atherosclerosis.2014.07.013","article-title":"Can osteoprotegerin be used to identify the presence and severity of coronary artery disease in different clinical settings?","volume":"236","author":"Hosbond","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.atherosclerosis.2015.03.028","article-title":"Low serum TNF-related apoptosis-inducing ligand (TRAIL) levels are associated with acute ischemic stroke severity","volume":"240","author":"Kang","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Pan, X., Pang, M., Ma, A., Wang, K., Zhang, Z., Zhong, Q., and Yang, S. (2015). Association of TRAIL and Its Receptors with Large-Artery Atherosclerotic Stroke. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136414"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fneur.2018.00102","article-title":"Follow-up Analysis of Serum TNF-Related Apoptosis-Inducing Ligand Protein and mRNA Expression in Peripheral Blood Mononuclear Cells from Patients with Ischemic Stroke","volume":"9","author":"Tufekci","year":"2018","journal-title":"Front. Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7705\/biomedica.5943","article-title":"The effectiveness of serum S100B, TRAIL, and adropin levels in predicting clinical outcome, final infarct core, and stroke subtypes of acute ischemic stroke patients","volume":"42","author":"Kucukdagli","year":"2022","journal-title":"Biom\u00e9dica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1161\/STROKEAHA.121.038349","article-title":"Longitudinal Study Reveals Long-Term Proinflammatory Proteomic Signature After Ischemic Stroke Across Subtypes","volume":"53","author":"Stanne","year":"2022","journal-title":"Stroke"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Mihalovic, M., Mikulenka, P., L\u00ednkov\u00e1, H., Neuberg, M., \u0160t\u011btk\u00e1\u0159ov\u00e1, I., Peisker, T., Lauer, D., and Tousek, P. (2022). Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) in Patients after Acute Stroke: Relation to Stroke Severity, Myocardial Injury, and Impact on Prognosis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11092552"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1161\/STROKEAHA.119.024379","article-title":"sTRAIL-R2 (Soluble TNF [Tumor Necrosis Factor]-Related Apoptosis-Inducing Ligand Receptor 2) a Marker of Plaque Cell Apoptosis and Cardiovascular Events","volume":"50","author":"Singh","year":"2019","journal-title":"Stroke"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.01.006","article-title":"Osteoprotegerin Assessment Improves Prediction of Mortality in Stroke Patients","volume":"28","author":"Wajda","year":"2019","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2796.2009.02163.x","article-title":"Osteoprotegerin concentrations and prognosis in acute ischaemic stroke","volume":"267","author":"Jensen","year":"2010","journal-title":"J. Intern. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"712","DOI":"10.12659\/MSM.889514","article-title":"Association of circulating sTRAIL and high-sensitivity CRP with type 2 diabetic nephropathy and foot ulcers","volume":"19","author":"Yalcin","year":"2013","journal-title":"Med. Sci. Monit."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e14489","DOI":"10.1097\/MD.0000000000014489","article-title":"Inverse regulation of serum osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand levels in patients with leg lesional vascular calcification: An observational study","volume":"98","author":"Moon","year":"2019","journal-title":"Medicine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/j.thromres.2010.09.003","article-title":"Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status","volume":"126","author":"Ashley","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/eurheartj\/ehp004","article-title":"Prognostic value of apoptosis markers in advanced heart failure patients","volume":"30","author":"Niessner","year":"2009","journal-title":"Eur. Heart J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.ijcard.2012.11.052","article-title":"A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure","volume":"168","author":"Richter","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e001633","DOI":"10.1161\/CIRCGENETICS.116.001633","article-title":"Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach","volume":"10","author":"Hage","year":"2017","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000346621","article-title":"Changes and prognostic impact of apoptotic and inflammatory cytokines in patients treated with cardiac resynchronization therapy","volume":"124","author":"Osmancik","year":"2013","journal-title":"Cardiology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ejhf.980","article-title":"Circulating proteins as predictors of incident heart failure in the elderly: Circulating proteins as predictors of incident heart failure","volume":"20","author":"Stenemo","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1161\/01.CIR.0000165119.62099.14","article-title":"Dysregulated osteoprotegerin\/RANK ligand\/RANK axis in clinical and experimental heart failure","volume":"111","author":"Ueland","year":"2005","journal-title":"Circulation"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.jacc.2004.06.076","article-title":"Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction","volume":"44","author":"Ueland","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ahj.2010.05.015","article-title":"Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial","volume":"160","author":"Roysland","year":"2010","journal-title":"Am. Heart J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.bbrc.2005.10.136","article-title":"TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy","volume":"338","author":"Schoppet","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/eurjhf\/hfp105","article-title":"Plasma concentrations of tumour necrosis factor-alpha, tumour necrosis factor-related apoptosis-inducing ligand, and FasLigand\/CD95L in patients with Chagas cardiomyopathy correlate with left ventricular dysfunction","volume":"11","author":"Lula","year":"2009","journal-title":"Eur. J. Heart Fail."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000319619","article-title":"Decreased Apoptosis following Successful Ablation of Atrial Fibrillation","volume":"116","author":"Osmancik","year":"2010","journal-title":"Cardiology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.clinbiochem.2013.02.003","article-title":"Association of post-cardioversion transcardiac concentration gradient of soluble tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL) and inflammatory biomarkers to atrial fibrillation recurrence","volume":"46","author":"Deftereos","year":"2013","journal-title":"Clin. Biochem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"259843","DOI":"10.1155\/2015\/259843","article-title":"Osteoprotegerin and TRAIL in Acute Onset of Atrial Fibrillation","volume":"2015","author":"Rewiuk","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/eurheartj\/ehy815","article-title":"Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation","volume":"40","author":"Chua","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ijcard.2011.11.099","article-title":"Osteoprotegerin\/RANK\/RANKL axis and atrial remodeling in mitral valvular patients with atrial fibrillation","volume":"166","author":"Cao","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"9547","DOI":"10.1096\/fj.201902785R","article-title":"Vascular transcriptome landscape of Trail\u2212\/\u2212 mice: Implications and therapeutic strategies for diabetic vascular disease","volume":"34","author":"Cartland","year":"2020","journal-title":"FASEB J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e002527","DOI":"10.1161\/JAHA.115.002527","article-title":"Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Angiogenesis and Ischemia-Induced Neovascularization Via NADPH Oxidase 4 (NOX4) and Nitric Oxide-Dependent Mechanisms","volume":"4","author":"Cartland","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/s41598-017-01721-4","article-title":"Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice","volume":"7","author":"Cartland","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.2337\/diabetes.52.9.2274","article-title":"Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes","volume":"52","author":"Zheng","year":"2003","journal-title":"Diabetes"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1007\/s00125-011-2308-0","article-title":"TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe\u2212\/\u2212 mice","volume":"54","author":"Chan","year":"2011","journal-title":"Diabetologia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.atherosclerosis.2011.01.010","article-title":"TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient mice","volume":"215","author":"Watt","year":"2011","journal-title":"Atherosclerosis"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.freeradbiomed.2018.08.031","article-title":"TRAIL protects against endothelial dysfunction in vivo and inhibits angiotensin-II-induced oxidative stress in vascular endothelial cells in vitro","volume":"126","author":"Cartland","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Cartland, S.P., Erlich, J.H., and Kavurma, M.M. (2014). TRAIL Deficiency Contributes to Diabetic Nephropathy in Fat-Fed ApoE\u2212\/\u2212 Mice. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0092952"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Di Bartolo, B.A., Cartland, S.P., Harith, H.H., Bobryshev, Y.V., Schoppet, M., and Kavurma, M.M. (2013). TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL. PLoS ONE, 8.","DOI":"10.1371\/annotation\/9732ca63-7532-4b92-8d6e-65c0863f25aa"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.106.643841","article-title":"Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice","volume":"114","author":"Secchiero","year":"2006","journal-title":"Circulation"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/01.ATV.0000166600.58468.1b","article-title":"Calcification of advanced atherosclerotic lesions in the innominate arteries of ApoE-deficient mice: Potential role of chondrocyte-like cells","volume":"25","author":"Rattazzi","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1161\/01.ATV.0000236428.91125.e6","article-title":"Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE\u2212\/\u2212 mice","volume":"26","author":"Bennett","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.atherosclerosis.2014.10.013","article-title":"TRAIL protects against endothelium injury in diabetes via Akt-eNOS signaling","volume":"237","author":"Liu","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00380-022-02197-7","article-title":"TRAIL inhibition by soluble death receptor 5 protects against acute myocardial infarction in rats","volume":"38","author":"Wang","year":"2022","journal-title":"Heart Vessels"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yjmcc.2019.08.011","article-title":"Death receptor 5 contributes to cardiomyocyte hypertrophy through epidermal growth factor receptor transactivation","volume":"136","author":"Tanner","year":"2019","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s10637-010-9627-8","article-title":"TRAIL shows potential cardioprotective activity","volume":"30","author":"Toffoli","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6529728","DOI":"10.1155\/2016\/6529728","article-title":"Dyslipidemia and Diabetes Increase the OPG\/TRAIL Ratio in the Cardiovascular System","volume":"2016","author":"Toffoli","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1097\/MD.0000000000000154","article-title":"Role of osteoprotegerin and its gene polymorphisms in the occurrence of left ventricular hypertrophy in essential hypertensive patients","volume":"93","author":"Shen","year":"2014","journal-title":"Medicine"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aaw3172","article-title":"Blocking the death checkpoint protein TRAIL improves cardiac function after myocardial infarction in monkeys, pigs, and rats","volume":"12","author":"Wang","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/1753-0407.12339","article-title":"Insulin promotes vascular smooth muscle cell proliferation and apoptosis via differential regulation of tumor necrosis factor-related apoptosis-inducing ligand","volume":"8","author":"Harith","year":"2016","journal-title":"J. Diabetes"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/jcb.24135","article-title":"Sp1, acetylated histone-3 and p300 regulate TRAIL transcription: Mechanisms of PDGF-BB-mediated VSMC proliferation and migration","volume":"113","author":"Azahri","year":"2012","journal-title":"J. Cell. Biochem."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Liu, F.F., Wu, X., Zhang, Y., Wang, Y., and Jiang, F. (2014). TRAIL\/DR5 signaling promotes macrophage foam cell formation by modulating scavenger receptor expression. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087059"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e14612","DOI":"10.14814\/phy2.14612","article-title":"TRAIL inhibits oxidative stress in human aortic endothelial cells exposed to pro-inflammatory stimuli","volume":"8","author":"Forde","year":"2020","journal-title":"Physiol. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1593\/neo.03421","article-title":"Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand","volume":"6","author":"Secchiero","year":"2004","journal-title":"Neoplasia"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.bbrc.2009.11.168","article-title":"Evidence that tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits angiogenesis by inducing vascular endothelial cell apoptosis","volume":"391","author":"Chen","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.4049\/jimmunol.171.3.1526","article-title":"TRAIL Induces Apoptosis and Inflammatory Gene Expression in Human Endothelial Cells 1","volume":"171","author":"Li","year":"2003","journal-title":"J. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.lfs.2004.11.029","article-title":"Involvement of death receptor signaling in mechanical stretch-induced cardiomyocyte apoptosis","volume":"77","author":"Liao","year":"2005","journal-title":"Life Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"44735","DOI":"10.1038\/srep44735","article-title":"Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/eurheartj\/ehz542","article-title":"Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1beta inhibition with canakinumab: Further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis","volume":"41","author":"Ridker","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/cen.12312","article-title":"Circulating level of TRAIL concentration is positively associated with endothelial function and increased by diabetic therapy in the newly diagnosed type 2 diabetic patients","volume":"80","author":"Xiang","year":"2014","journal-title":"Clin. Endocrinol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/j.diabres.2012.02.028","article-title":"Circulating soluble tumor necrosis factor related apoptosis inducing-ligand (TRAIL) is decreased in type-2 newly diagnosed, non-drug using diabetic patients","volume":"96","author":"Bisgin","year":"2012","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.diabres.2010.11.034","article-title":"Association of serum TRAIL levels with atherosclerosis in patients with type 2 diabetes mellitus","volume":"91","author":"Kawano","year":"2011","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/jcp.21006","article-title":"Insulin down-regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitro","volume":"212","author":"Corallini","year":"2007","journal-title":"J. Cell. Physiol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Koliaki, C., and Katsilambros, N. (2022). Repositioning the Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) on the TRAIL to the Development of Diabetes Mellitus: An Update of Experimental and Clinical Evidence. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063225"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MOL.0000000000000394","article-title":"The walking dead: Macrophage inflammation and death in atherosclerosis","volume":"28","author":"Kavurma","year":"2017","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s12975-019-00755-2","article-title":"From Stroke to Dementia: A Comprehensive Review Exposing Tight Interactions Between Stroke and Amyloid-\u03b2 Formation","volume":"11","author":"Goulay","year":"2020","journal-title":"Transl. Stroke Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s12975-021-00921-5","article-title":"Is Cerebral Amyloid-\u03b2 Deposition Related to Post-stroke Cognitive Impairment?","volume":"12","author":"Ouyang","year":"2021","journal-title":"Transl. Stroke Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1038\/cddis.2012.55","article-title":"TRAIL death receptors DR4 and DR5 mediate cerebral microvascular endothelial cell apoptosis induced by oligomeric Alzheimer\u2019s A\u03b2","volume":"3","author":"Fossati","year":"2012","journal-title":"Cell Death Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/01.ATV.0000204334.48195.6a","article-title":"Enhanced T-cell expression of RANK ligand in acute coronary syndrome: Possible role in plaque destabilization","volume":"26","author":"Sandberg","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_100","unstructured":"Feingold, K.R., Anawalt, B., Blackman, M.R., Boyce, A., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., Hofland, J., and Dungan, K. (2000). Endotext, MDtext."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jacc.2019.07.020","article-title":"Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week","volume":"74","author":"Wang","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jss.2006.11.013","article-title":"Preferential Existence of Death-Inducing Proteins in the Human Cardiomyopathic Left Ventricle","volume":"142","author":"Dzimiri","year":"2007","journal-title":"J. Surg. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1369\/jhc.3A6112.2004","article-title":"Tissue Distribution of the Death Ligand TRAIL and Its Receptors","volume":"52","author":"Spierings","year":"2004","journal-title":"J. Histochem. Cytochem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0735-1097(02)02959-5","article-title":"Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure","volume":"41","author":"Abbate","year":"2003","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6725\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:09:43Z","timestamp":1760123383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":104,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijms24076725"],"URL":"https:\/\/doi.org\/10.3390\/ijms24076725","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]}}}